IMMUNOMODULATORY PROPERTIES OF INTERFERON ALPHA AND RIBAVIRIN

Size: px
Start display at page:

Download "IMMUNOMODULATORY PROPERTIES OF INTERFERON ALPHA AND RIBAVIRIN"

Transcription

1 IMMUNOMODULATORY PROPERTIES OF INTERFERON ALPHA AND RIBAVIRIN Nikolai V. Naoumov UCL Institute of Hepatology University College London Chenies Mews London WC1E 6HX UK Key concepts: Interferon-alpha has a broad spectrum of immunomodulatory activities on both innate and adaptive immune responses. Ribavirin has immunomodulatory properties and both in vitro and in vivo was shown to modulate the cytokine profile. The greater efficacy of interferon-alpha plus ribavirin therapy is a result of multiple synergistic effects including antiviral activity, favourable cytokine profile, increased antiviral T-cell reactivity in fast-responders, upregulation of antiviral gene expression. In hepatitis C treatment, interferon-alpha and ribavirin appear to work mainly by direct interference with HCV life cycle, rather than by enhancement of cellular immunity to HCV. Interferon-alpha (IFN-α) has been the mainstay of treatment for hepatitis C even before the identification of the hepatitis C virus (HCV). The initial results with recombinant IFN-α or with natural, lymphoblastoid IFN-α alone were disappointing with only a small proportion of patients achieving a sustained virological response. The empirical addition of ribavirin to standard interferon significantly improved the long-term virological response. The development of pegylated interferons led to further improvement in the treatment outcome, and currently the combination of pegylated IFN-α plus ribavirin is the standard of care for antiviral therapy in patients with chronic hepatitis C. Both IFN-α and ribavirin possess broad spectrum antiviral and immunomodulatory activities, however the mechanisms of action of these two drugs in hepatitis C treatment, and the hierarchy of their effects in achieving HCV clearance are not fully understood. Immunomodulatory properties of IFN-α IFN-α belongs to the family of type I interferons, which in humans include IFN-α (a mixture of 13 different subtypes - IFN-α1, α2, etc), IFN-β, IFN-ε, IFN-κ and IFN-ω (1). Type I interferons are produced by most cells in response to viral or bacterial infections and have a central role in the innate immune response to pathogens. All type I interferons bind to a common cell surface receptor, which is known as type I IFN-receptor, in contrast to the only type II interferon, IFN-γ, which binds to type II IFN-receptor (Figure 1). IFN-α mediates a wide range of biological effects including direct antiviral, immunomodulatory, antiproliferative, antiangiogenic and antitumour activities (2). The potent direct antiviral effect of IFN-α against HCV was recently demonstrated 1

2 using the new HCV genotype 2a replicon (clone JFH-1)(3). In concentrations comparable to the clinical levels, IFN-α and ribavirin reduced HCV replication down to 0.09% and 54% of baseline levels, respectively, while the combination of the two agents showed about 1.5-fold greater antiviral activity than IFN-α alone (3). In addition to the direct antiviral effect, IFN-α has a broad spectrum of immunomodulatory activities on both innate and adaptive immune responses. These include upregulation of major histocompatibity complex (MHC) class-i and class II, increased natural killer cell activity, enhancement of dendritic cell (DC) activation. In vitro studies with monocyte-derived dendritic cells from healthy donors showed that IFN-α increases DCallostimulatory capacity (4). When DC were stimulated simultaneously with IFN-α and CD40 ligation, the production of both IL-10 and IL-12 was increased; while the stimulation with IFN-α plus lipopolisaccharide (LPS) enhanced mainly IL-10 production (4). In another study, also using DC from healthy donors, IFN-α alone was shown to increase MHC class I, class II and CD86 molecules on immature DC, and it also stimulated IL-12 and TNF-α production (5). In contrast, ribavirin in vitro had no effect on DC maturation, but markedly suppressed the production of TNF-alpha, IL-10 and IL-12. HCV infection has a major and multidirectional impact on dendritic cell function (6) and the relevance of the findings with DC from healthy donors for the treatment outcome in chronic hepatitis C is not established. The multiple immunomodulatory properties of therapeutic IFN-α were recently demonstrated using microarrays detecting directly the gene expression profile in peripheral blood mononuclear cells (PCMC) from patients with HCV infection (7,8). After a single application of IFN-α there was a significant upregulation of 88 genes involved in antigen processing and presentation, T-cell activation, lymphocyte trafficking and effector functions. PBMC after one IFN-α infection, showed a substantial increase in IL-10 production, both in response to antigen-specific and non-specific stimulation, while lymphocyte proliferation was decreased in comparison to PBMC prior to IFN-α injection. Immunomodulatory properties of Ribavirin Ribavirin is a synthetic guanosine analogue with a broad spectrum of antiviral activity, initially approved for treatment of respiratory syncytial virus (RSV) infection. Several mechanisms have been proposed by which ribavirin may be beneficial for the treatment of chronic hepatitis C (reviewed in 9, Figure 2). This summary is focused only on the immunomodulatory properties of Ribavirin. In vitro experiments, using mitogen-stimulated PBMC have shown that ribavirin promotes T helper 1 (Th1) reactivity, while inhibiting Th2 cytokine production (10). Importantly, the immunomodulatory properties of ribavirin appear to vary at different concentrations - at low concentrations ribavirin appears to potentiate Th1-pattern of immune responses. In contrast, at higher concentrations (above 5 µg/ml) ribavirin inhibits lymphocyte proliferation and has an immunosuppressive effect. Other studies have also shown that ribavirin can modulate T-cell reactivity and/or cytokine profile, however, the direct effect of ribavirin on HCV-specific T-cell reactivity from patients with hepatitis C has not been defined. As Ribavirin is a purine analogue, it may exert immunomodulatory activities via toll-like receptor (TLR). However, Ribavirin did not stimulate TLR7 or TLR8-mediated signaling in cells transfected with these TLRs (11). A possible mechanism by which ribavirin may exert a a synergistic effect with IFN-α is indicated by the finding that ribavirin upregulates antiviral gene expression via the interferon-stimulated response element in RSV-infected cells (12). 2

3 Immunomodulatory properties of IFN-α and Ribavirin during treatment of hepatitis C The effects of IFN-α and Ribavirin on the immune responses of patients undergoing treatment for hepatitis C are complex and may result from: a) direct immonomodulatory properties of each agent; b) the indirect effect of treatment-induced suppression of HCV replication and decreased viraemia levels on antiviral immune reactivity; c) the interaction between these two agents with their multifunctional effects. In a prospective study we analysed CD4+ T-cell proliferation, together with IFN-gamma and IL-10 production in response to HCV antigens, during treatment with IFN-α alone or in combination with Ribavirin (13). Undetectable HCV viraemia was associated with enhanced CD4+ T-cell reactivity to viral antigens. Importantly, the main difference in the T-cell resposne to HCV antigens of patients treated with the combination of IFN-α plus ribavirin was a significantly lower production of IL-10 in comparison to those treated with IFN-α alone, while there was no significant difference in the IFN-gamma production (Figure 3). These results indicated that the greater efficacy of the combination therapy may be related to its ability to suppress HCV-specific IL-10 production (13). Characterisation of T-cell reactivity during treatment of patients with acute hepatitis C has shown that the outcome of early treatment of acute HCV infection is not associated with enhanced CD4 or CD8+ T-cell reactivity to HCV (14,15). The changes of antiviral T-cell reactivity during treatment of chronic hepatitis C patients with IFN-α plus Ribavirin may be influenced also by patients ethnicity and the HCV genotype (16). Recently, we studied the relationship between early HCV kinetics and antiviral T- cell reactivity in a homogeneous group of patients with HCV genotype 1 chronic hepatitis C (17). Although all patients received the same treatment with pegylated IFN-α2a plus Ribavirin, enhanced frequency of HCV-specific CD4+ and CD8+ T-cells was observed only in fast responders to treatment (Figure 4), thus indicating that the enhanced T-cell reactivity was a consequence of rapid viraemia clearance, rather than a result of direct immunostimulatory effects of IFN-α plus Ribavirin. Collectively, the accumulating evidence suggests that the greater efficacy of IFN-α plus Ribavirin combination therapy is a result of multiple synergistic effects of these agents. These include enhanced antiviral activity (3), ribavirin-induced control of interferon-stimulated IL-10 production (8,13), transient increase of adaptive immunity in fast responders (17), ribavirinupregulated antiviral gene expression via the interferon-stimulated response element (12), and the possibility that ribavirin decreases HCV infectivity during the course of combination therapy (18). References: 1. Platanias LC. Mechanisms of type-i- and type-ii-interferon-mediated signalling. Nat Rev Immunol. 2005;5(5): Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol. 2005;23: Kato T, Date T, Miyamoto M, Sugiyama M, Tanaka Y, Orito E, Ohno T, Sugihara K, Hasegawa I, Fujiwara K, Ito K, Ozasa A, Mizokami M, Wakita T. Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system. J Clin Microbiol. 2005; 43(11): Tamir A, Jordan WJ, Ritter M, Habib N, Lechler RI, Foster GR, Lombardi G. Interferonalpha2a is sufficient for promoting dendritic cell immunogenicity. Clin Exp Immunol. 2005; 142(3):

4 5. Barnes E, Salio M, Cerundolo V, Medlin J, Murphy S, Dusheiko G, Klenerman P. Impact of alpha interferon and ribavirin on the function of maturing dendritic cells. Antimicrob Agents Chemother. 2004;48(9): Pachiadakis I, Pollara G, Chain BM, Naoumov NV. Is hepatitis C virus infection of dendritic cells a mechanism facilitating viral persistence? Lancet Infect Dis. 2005;5(5): Ji X, Cheung R, Cooper S, Li Q, Greenberg HB, He XS. Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology. 2003; 37(3): Luik A, Knapp S, Thursz M, Thomas HC, Schlaak JF. Autoregulatory role of interleukin-10 in hepatitis C patients treated with IFN-alpha. J Interferon Cytokine Res. 2004;24(10): Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology. 2002;35(5): Tam RC, Pai B, Bard J, Lim C, Averett DR, Phan UT, Milovanovic T. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol. 1999;30(3): Vollmer J, Rankin R, Hartmann H, Jurk M, Samulowitz U, Wader T, Janosch A, Schetter C, Krieg AM. Immunopharmacology of CpG oligodeoxynucleotides and ribavirin. Antimicrob Agents Chemother. 2004;48(6): Zhang Y, Jamaluddin M, Wang S, Tian B, Garofalo RP, Casola A, Brasier AR. Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J Virol. 2003;77(10): Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virusspecific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology. 2000;118(2): Rahman F, Heller T, Sobao Y, Mizukoshi E, Nascimbeni M, Alter H, Herrine S, Hoofnagle J, Liang TJ, Rehermann B. Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology. 2004;40(1): Lauer GM, Lucas M, Timm J, Ouchi K, Kim AY, Day CL, et al. Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J Virol. 2005; 79(20): Kaplan DE, Sugimoto K, Ikeda F, Stadanlick J, Valiga M, Shetty K, Reddy KR, Chang KM. T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C. Hepatology. 2005;41(6): Tang KH, Herrmann E, Cooksley H, Tatman N, Chokshi S, Williams R, Zeuzem S, Naoumov NV. Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy. J Hepatol. 2005;43(5): Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature. 2004;432(7019):

5 Figure 1. Interferon receptors and activation of classical pathways by type I and type II interferons (from reference 1 - reproduced with permission from Nature Reviews Immunology (Vol.5, No.5, pp , 2005), copyright (2005) Macmillan Magazines Ltd.). 5

6 Figure 2. Possible immunomodulatory and direct antiviral activities of ribavirin: (i) drug-induced immune clearance of the virus by facilitating the switch from a Th 2 to a Th 1 phenotype with increased production of antiviral cytokines such as TNF and IFN-gamma; (ii) RMP inhibits the enzymatic activity of IMPDH in the conversion of IMP into GMP; (iii) inhibition of HCV RdRp activity; (iv) Ribavirin, triphosphate (RTP) acts as an RNA mutagen. The combined direct antiviral activities of steps (ii) (iv) result in down-regulation of HCV virion production while HCV particles that are released are defective. CTL, cytotoxic T lymphocytes; HCV, hepatitis C virus; IFN, interferon; IMP, inosine monophosphate; IMPDH, inosine monophosphate dehydrogenase; RDP, ribavirin diphosphate; RdRp, RNA-dependent RNA polymerase; RMP, ribavirin monophosphate; RTP, ribavirin triphosphate; TNF, tumour necrosis factor; RNA, ribonucleic acid (from reference 9 - Hepatology 2002;35(5), pp reproduced with permission of Wiley-Liss, Inc. a subsidiary of John Wiley & Sons, Inc.) 6

7 Figure 3. Changes in HCV-specific IL-10 and IFN-γ production in vitro from patients treated with IFN alone and with IFN plus Ribavirin. The values for IL-10 and IFN-γ represent the difference in the cytokine levels produced from PBMCs cultured in the presence of HCV antigens minus that produced by cells cultured in medium alone. Figure 4. Frequencies of HCV-specific T-cells producing IFN-γ in response to HCV antigens, as determined by ELISpot assay. A) CD4+ T-cells stimulated with HCV Core, NS3 and NS4; B) CD8+ T-cells stimulated with HLA-A2 restricted peptides. TW-treatment week; FR-fastresponders, SR-slow/flat responders. 7

ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT

ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes

More information

Medical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University

Medical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve

More information

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes: Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,

More information

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes: Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,

More information

Immunology lecture: 14. Cytokines: Main source: Fibroblast, but actually it can be produced by other types of cells

Immunology lecture: 14. Cytokines: Main source: Fibroblast, but actually it can be produced by other types of cells Immunology lecture: 14 Cytokines: 1)Interferons"IFN" : 2 types Type 1 : IFN-Alpha : Main source: Macrophages IFN-Beta: Main source: Fibroblast, but actually it can be produced by other types of cells **There

More information

EFFECT OF INTERFERON AND RIBAVIRIN ON HEPATITIS C VIRUS

EFFECT OF INTERFERON AND RIBAVIRIN ON HEPATITIS C VIRUS EFFECT OF INTERFERON AND RIBAVIRIN ON HEPATITIS C VIRUS A Project Report Submitted in Partial Fulfilment of the Requirements For The Degree of Bachelor of Technology in Biomedical Engineering By Saraswati

More information

Structure and Function of Antigen Recognition Molecules

Structure and Function of Antigen Recognition Molecules MICR2209 Structure and Function of Antigen Recognition Molecules Dr Allison Imrie allison.imrie@uwa.edu.au 1 Synopsis: In this lecture we will examine the major receptors used by cells of the innate and

More information

TCR, MHC and coreceptors

TCR, MHC and coreceptors Cooperation In Immune Responses Antigen processing how peptides get into MHC Antigen processing involves the intracellular proteolytic generation of MHC binding proteins Protein antigens may be processed

More information

Cytokines (II) Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel:

Cytokines (II) Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel: Cytokines (II) Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel: 4677363 aalshamsan@ksu.edu.sa Learning Objectives By the end of this lecture you will be able to: 1 Understand the physiological

More information

The Adaptive Immune Responses

The Adaptive Immune Responses The Adaptive Immune Responses The two arms of the immune responses are; 1) the cell mediated, and 2) the humoral responses. In this chapter we will discuss the two responses in detail and we will start

More information

Role of Innate Immunity in Hepatitis B Virus Infection Adam J. Gehring, Ph.D.

Role of Innate Immunity in Hepatitis B Virus Infection Adam J. Gehring, Ph.D. Role of Innate Immunity in Hepatitis B Virus Infection Adam J. Gehring, Ph.D. Biology Lead Toronto Centre for Liver Disease Toronto General Hospital Research Institute University Health Network (UHN) HBV

More information

Immune response to infection

Immune response to infection Immune response to infection Dr. Sandra Nitsche (Sandra.Nitsche@rub.de ) 20.06.2018 1 Course of acute infection Typical acute infection that is cleared by an adaptive immune reaction 1. invasion of pathogen

More information

CYTOKINE RECEPTORS AND SIGNAL TRANSDUCTION

CYTOKINE RECEPTORS AND SIGNAL TRANSDUCTION CYTOKINE RECEPTORS AND SIGNAL TRANSDUCTION What is Cytokine? Secreted popypeptide (protein) involved in cell-to-cell signaling. Acts in paracrine or autocrine fashion through specific cellular receptors.

More information

Interferon-based and interferon-free new treatment options

Interferon-based and interferon-free new treatment options Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt

More information

Significance of the MHC

Significance of the MHC CHAPTER 7 Major Histocompatibility Complex (MHC) What is is MHC? HLA H-2 Minor histocompatibility antigens Peter Gorer & George Sneell (1940) Significance of the MHC role in immune response role in organ

More information

Basis and Clinical Applications of Interferon

Basis and Clinical Applications of Interferon Interferon Therapy Basis and Clinical Applications of Interferon JMAJ 47(1): 7 12, 2004 Jiro IMANISHI Professor, Kyoto Prefectural University of Medicine Abstract: Interferon (IFN) is an antiviral substance

More information

Retrospective analysis of chronic hepatitis C in untreated patients with nonlinear mixed effects model

Retrospective analysis of chronic hepatitis C in untreated patients with nonlinear mixed effects model J. Biomedical Science and Engineering, 2008, 1 8-90 Retrospective analysis of chronic hepatitis C in untreated patients with nonlinear mixed effects model Jian Huang 1, Kathleen O Sullivan 1, John Levis

More information

1. Overview of Adaptive Immunity

1. Overview of Adaptive Immunity Chapter 17A: Adaptive Immunity Part I 1. Overview of Adaptive Immunity 2. T and B Cell Production 3. Antigens & Antigen Presentation 4. Helper T cells 1. Overview of Adaptive Immunity The Nature of Adaptive

More information

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 13 Effector Responses: Cell- and Antibody-Mediated Immunity Copyright 2013 by W. H.

More information

SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM

SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN Background Hepatitis

More information

Basis of Immunology and

Basis of Immunology and Basis of Immunology and Immunophysiopathology of Infectious Diseases Jointly organized by Institut Pasteur in Ho Chi Minh City and Institut Pasteur with kind support from ANRS & Université Pierre et Marie

More information

HCV Resistance Associated variants: impact on chronic hepatitis C treatment

HCV Resistance Associated variants: impact on chronic hepatitis C treatment HCV Resistance Associated variants: impact on chronic hepatitis C treatment Dr. Stéphane Chevaliez Associate Professor of Medicine at the University of Paris-Est. History of Resistance in HCV Concern Only

More information

Oral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside

Oral combination therapy: future hepatitis C virus treatment? Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following

More information

The Immune System. These are classified as the Innate and Adaptive Immune Responses. Innate Immunity

The Immune System. These are classified as the Innate and Adaptive Immune Responses. Innate Immunity The Immune System Biological mechanisms that defend an organism must be 1. triggered by a stimulus upon injury or pathogen attack 2. able to counteract the injury or invasion 3. able to recognise foreign

More information

Principles of Adaptive Immunity

Principles of Adaptive Immunity Principles of Adaptive Immunity Chapter 3 Parham Hans de Haard 17 th of May 2010 Agenda Recognition molecules of adaptive immune system Features adaptive immune system Immunoglobulins and T-cell receptors

More information

INTRODUCTION. Division of Gastroenterology, Institute of Clinical Medicine, University of Tsukuba, Tennoudai, Tsukuba, Ibaraki , Japan

INTRODUCTION. Division of Gastroenterology, Institute of Clinical Medicine, University of Tsukuba, Tennoudai, Tsukuba, Ibaraki , Japan Journal of General Virology (2004), 85, 1521 1531 DOI 10.1099/vir.0.79801-0 Identification of novel hepatitis C virus-specific cytotoxic T lymphocyte epitopes by ELISpot assay using peptides with human

More information

Interleukin-12 P40 (IL-12 B) Taq-1 Polymorphism association in pharmacogenomics of HCV genotype 3a infection from Pakistani population

Interleukin-12 P40 (IL-12 B) Taq-1 Polymorphism association in pharmacogenomics of HCV genotype 3a infection from Pakistani population 2011 International Conference on Environmental, Biomedical and Biotechnology IPCBEE vol.16 (2011) (2011)IACSIT Press, Singapoore Interleukin-12 P40 (IL-12 B) Taq-1 Polymorphism association in pharmacogenomics

More information

Cytokines modulate the functional activities of individual cells and tissues both under normal and pathologic conditions Interleukins,

Cytokines modulate the functional activities of individual cells and tissues both under normal and pathologic conditions Interleukins, Cytokines http://highered.mcgraw-hill.com/sites/0072507470/student_view0/chapter22/animation the_immune_response.html Cytokines modulate the functional activities of individual cells and tissues both under

More information

IL-17 in health and disease. March 2014 PSO13-C051n

IL-17 in health and disease. March 2014 PSO13-C051n IL-17 in health and disease March 2014 PSO13-C051n Originally Researchers Suggested That IL-12 and IL-4 drove Th Cell Differentiation Naïve CD4 + T cell Question: Which of these cell types is responsible

More information

Viral dynamics and Resistance Implications for HCV drug development

Viral dynamics and Resistance Implications for HCV drug development Viral dynamics and Resistance Implications for HCV drug development Robert T. Schooley, M.D. University of California, San Diego June 23, 2011 SVR Rate Priorities in HCV Therapeutics 100 90 80 70 60 50

More information

Approximately 200 million individuals worldwide

Approximately 200 million individuals worldwide Triphasic Decline of Hepatitis C Virus RNA During Antiviral Therapy Harel Dahari, Ruy M. Ribeiro, and Alan S. Perelson When patients chronically infected with hepatitis C virus (HCV) are placed on antiviral

More information

29th Viral Hepatitis Prevention Board Meeting

29th Viral Hepatitis Prevention Board Meeting 29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis C José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HEPATITIS C

More information

Antigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS

Antigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS 1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family

More information

Horizon 2020 Programme. SFS-01b Tackling losses from terrestrial animal diseases

Horizon 2020 Programme. SFS-01b Tackling losses from terrestrial animal diseases Horizon 2020 Programme SFS-01b-2014 Tackling losses from terrestrial animal diseases Strengthening Animal Production and Health through the Immune Response Project ID: 633184 D12.1 Age related innate responses

More information

IOM Immunization Safety Review 11/12/2001. Immunological Competition and the Infant Immune Response to Vaccines

IOM Immunization Safety Review 11/12/2001. Immunological Competition and the Infant Immune Response to Vaccines IOM Immunization Safety Review 11/12/2001 Immunological Competition and the Infant Immune Response to Vaccines Richard Insel University of Rochester Goals Neonatal and Infant Immune System Broad Effects

More information

M.Sc. III Semester Biotechnology End Semester Examination, 2013 Model Answer LBTM: 302 Advanced Immunology

M.Sc. III Semester Biotechnology End Semester Examination, 2013 Model Answer LBTM: 302 Advanced Immunology Code : AS-2246 M.Sc. III Semester Biotechnology End Semester Examination, 2013 Model Answer LBTM: 302 Advanced Immunology A. Select one correct option for each of the following questions:- 2X10=10 1. (b)

More information

AGAINST VIRAL INFECTIONS. Identify the types of immunity involve in the mechanisms of protection against viral infections.

AGAINST VIRAL INFECTIONS. Identify the types of immunity involve in the mechanisms of protection against viral infections. LECTURE: 02 Title: THE IMMUNOLOGICAL PROTECTIVE MECHANISMS AGAINST VIRAL INFECTIONS LEARNING OBJECTIVES: The student should be able to: Identify the types of immunity involve in the mechanisms of protection

More information

Hepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement

Hepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement Hepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement Fabien Zoulim Service d hépatologie, Hospices Civils de Lyon INSERM U1052, Cancer

More information

Helminth worm, Schistosomiasis Trypanosomes, sleeping sickness Pneumocystis carinii. Ringworm fungus HIV Influenza

Helminth worm, Schistosomiasis Trypanosomes, sleeping sickness Pneumocystis carinii. Ringworm fungus HIV Influenza Helminth worm, Schistosomiasis Trypanosomes, sleeping sickness Pneumocystis carinii Ringworm fungus HIV Influenza Candida Staph aureus Mycobacterium tuberculosis Listeria Salmonella Streptococcus Levels

More information

Adaptive Immunity: Humoral Immune Responses

Adaptive Immunity: Humoral Immune Responses MICR2209 Adaptive Immunity: Humoral Immune Responses Dr Allison Imrie 1 Synopsis: In this lecture we will review the different mechanisms which constitute the humoral immune response, and examine the antibody

More information

Chapter 22: The Lymphatic System and Immunity

Chapter 22: The Lymphatic System and Immunity Bio40C schedule Lecture Immune system Lab Quiz 2 this week; bring a scantron! Study guide on my website (see lab assignments) Extra credit Critical thinking questions at end of chapters 5 pts/chapter Due

More information

General Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center

General Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center General Overview of Immunology Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center Objectives Describe differences between innate and adaptive immune responses

More information

Antiviral Chemotherapy

Antiviral Chemotherapy Viruses are intimate intracellular parasites and their destruction may cause destruction of infected cells. Many virus infections were considered to be self-limited. Most of the damage to cells in virus

More information

Immunity to Viruses. Patricia Fitzgerald-Bocarsly September 25, 2008

Immunity to Viruses. Patricia Fitzgerald-Bocarsly September 25, 2008 Immunity to Viruses Patricia Fitzgerald-Bocarsly September 25, 2008 The Immune System Deals with a Huge Range of Pathogens Roitt, 2003 Immune Responses to Viruses Viruses are dependent on the host cell

More information

0105) at the day 15, respectively1 In contrast, the percentages of CD3 + CD4 + and NK cells displayed no

0105) at the day 15, respectively1 In contrast, the percentages of CD3 + CD4 + and NK cells displayed no 2003 12 10 83 23 Natl Med J China, December 10,2003,Vol 83, No. 23 2049 (CIK ), T, CIK 13 (PBMC),,4 7 10 13 15 ;CIK, (DC1) (CD2),CD3 + CD8 +, CD3 + CD56 +, CD25 +, 3315 % 1011 % 717 % 218 %1213 % 415 %,3616

More information

Intron A Hepatitis B. Intron A (interferon alfa-2b) Description

Intron A Hepatitis B. Intron A (interferon alfa-2b) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.01 Subject: Intron A Hepatitis B Page: 1 of 7 Last Review Date: November 30, 2018 Intron A Hepatitis

More information

Antiviral therapy guidelines for the general population

Antiviral therapy guidelines for the general population Discussion 10 Chapter 10 Hepatitis C a worldwide problem More than 170 million people worldwide suffer from chronic hepatitis C. Its prevalence is 2% in industrialized countries. 1 Approximately 20% of

More information

Direct acting anti-virals: the near future

Direct acting anti-virals: the near future Direct acting anti-virals: the near future Heiner Wedemeyer Hannover Medical School Germany Will IFN-free treatment be possible in the near future? Interferon-free regimens to treat hepatitis C What should

More information

Hepatitis C Virus and Cytokine Responses

Hepatitis C Virus and Cytokine Responses Hepatitis C Virus and Cytokine Responses Eui-Cheol Shin, M.D., Ph.D. Laboratory of Immunology & Infectious Diseases (LIID), Graduate School of Medical Science & Engineering (GSMSE), KAIST Daejeon, Korea

More information

T Cell Activation. Patricia Fitzgerald-Bocarsly March 18, 2009

T Cell Activation. Patricia Fitzgerald-Bocarsly March 18, 2009 T Cell Activation Patricia Fitzgerald-Bocarsly March 18, 2009 Phases of Adaptive Immune Responses Phases of T cell responses IL-2 acts as an autocrine growth factor Fig. 11-11 Clonal Expansion of T cells

More information

The Adaptive Immune Response. T-cells

The Adaptive Immune Response. T-cells The Adaptive Immune Response T-cells T Lymphocytes T lymphocytes develop from precursors in the thymus. Mature T cells are found in the blood, where they constitute 60% to 70% of lymphocytes, and in T-cell

More information

LYMPHOCYTES & IMMUNOGLOBULINS. Dr Mere Kende, Lecturer SMHS

LYMPHOCYTES & IMMUNOGLOBULINS. Dr Mere Kende, Lecturer SMHS LYMPHOCYTES & IMMUNOGLOBULINS Dr Mere Kende, Lecturer SMHS Immunity Immune- protection against dangers of non-self/invader eg organism 3 components of immune system 1 st line: skin/mucosa/cilia/hair/saliva/fatty

More information

Pilot study of interferon gamma for chronic hepatitis C *

Pilot study of interferon gamma for chronic hepatitis C * Journal of Hepatology 43 (2005) 67 71 www.elsevier.com/locate/jhep Pilot study of interferon gamma for chronic hepatitis C * Alejandro Soza 1, Theo Heller 1, Marc Ghany 1, Glen Lutchman 1, T. Jake Liang

More information

Hepatitis C in Australia:

Hepatitis C in Australia: Hepatitis C in Australia: Epidemiology and Clinical Presentation (and a bit of virology ) A/Prof Mark Douglas Hepatitis C - Distribution Te and Jensen 2010 Clin Liver Dis Hepatitis C Epidemiology Estimated

More information

HCV MEDICATIONS & Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati

HCV MEDICATIONS & Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati HCV MEDICATIONS & THERAPEUTIC TRIALS Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati DISCLOSURES Active or Within 12 Months Research

More information

Keywords: inosine pranobex, rapid Isoprinosine response, large lymphocytes / monocytes number

Keywords: inosine pranobex, rapid Isoprinosine response, large lymphocytes / monocytes number Isoprinosine Induces a Rapid Lympho - Mononuclear Response in Adult Participants Zahariy Krastev, Deian Jelev, Radina Ivanova University Hospital St. Ivan Rilski Gastroenterology Sofia, Clinic of Abstract

More information

Title: NATURAL KILLER CELL FUNCTIONS AND SURFACE RECEPTORS

Title: NATURAL KILLER CELL FUNCTIONS AND SURFACE RECEPTORS LECTURE: 14 Title: NATURAL KILLER CELL FUNCTIONS AND SURFACE RECEPTORS LEARNING OBJECTIVES: The student should be able to: Describe the general morphology of the NK-cells. Enumerate the different functions

More information

Engineered Immune Cells for Cancer Therapy : Current Status and Prospects

Engineered Immune Cells for Cancer Therapy : Current Status and Prospects When Engineering Meets Immunology Engineered Immune Cells for Cancer Therapy : Current Status and Prospects Yong Taik Lim, Ph.D. Nanomedical Systems Laboratory (http://www.nanomedicalsystems.org) SKKU

More information

1. TLR. TLR Toll-like receptors. Toll Toll-like receptor, TLR TLR TLR TLR. type I TLR TLR. Toll

1. TLR. TLR Toll-like receptors. Toll Toll-like receptor, TLR TLR TLR TLR. type I TLR TLR. Toll 54pp.145 152 2004 1. TLR T B TLR Toll-like receptors TLR TLR I IFN TLR T B B T Toll NF- B 1996 565-0871 3-1 TEL 06-6879-8303 FAX 06-6879-8305 E-mail uemattsu@biken.osaka-u.ac.jp Toll Toll-like receptor,

More information

SINGLE CHOICE. 5. The gamma invariant chain binds to this molecule during its intracytoplasmic transport. A TCR B BCR C MHC II D MHC I E FcγR

SINGLE CHOICE. 5. The gamma invariant chain binds to this molecule during its intracytoplasmic transport. A TCR B BCR C MHC II D MHC I E FcγR A Name: Group: SINGLE CHOICE 1. Which is the most important ligand of TLR5? A endospore B flagellin C polysaccharide capsule D DNA E pilus 2. The antibody-binding site is formed primarily by... A the constant

More information

The g c Family of Cytokines Prof. Warren J. Leonard M.D.

The g c Family of Cytokines Prof. Warren J. Leonard M.D. The Family of Cytokines Chief, Laboratory of Molecular Immunology Director, Immunology Center National Heart, Lung, and Blood Institute National Institutes of Health Department of Health and Human Services

More information

CHARACTERIZATION OF V36C, A NOVEL AMINO ACID SUBSTITUTION CONFERRING HEPATITIS C VIRUS (HCV) RESISTANCE TO TELAPREVIR, A

CHARACTERIZATION OF V36C, A NOVEL AMINO ACID SUBSTITUTION CONFERRING HEPATITIS C VIRUS (HCV) RESISTANCE TO TELAPREVIR, A AAC Accepts, published online ahead of print on 5 April 2010 Antimicrob. Agents Chemother. doi:10.1128/aac.01796-09 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions.

More information

Analysis of the relationship between peripheral blood T lymphocyte subsets and HCV RNA levels in patients with chronic hepatitis C

Analysis of the relationship between peripheral blood T lymphocyte subsets and HCV RNA levels in patients with chronic hepatitis C Analysis of the relationship between peripheral blood T lymphocyte subsets and HCV RNA levels in patients with chronic hepatitis C Y. Huang, M.J. Zheng and Y.H. Xu Laboratory, First Affiliated Hospital

More information

Review Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3

Review Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3 Review Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3 Thomas Berg 1 * and Giampiero Carosi 2 Antiviral Therapy 13 Suppl 1:17 22 1 Charite Universitatsmedizin Berlin, Berlin, Germany

More information

Treatment choices for people infected with HCV

Treatment choices for people infected with HCV Journal of Antimicrobial Chemotherapy (2004) 53, 708 712 DOI: 10.1093/jac/dkh170 Treatment choices for people infected with HCV Silvia Fargion*, Anna Ludovica Fracanzani and Luca Valenti Dipartimento di

More information

The HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany

The HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany : Will IFN-free treatment be possible? Heiner Wedemeyer Hannover Medical School Germany Interferon-free regimens to treat hepatitis C What should be the goal of interferon-free treatment regimens: Sustained

More information

Effector Mechanisms of Cell-Mediated Immunity

Effector Mechanisms of Cell-Mediated Immunity Effector Mechanisms of Cell-Mediated Immunity Dr. Julia Rempel Section of Hepatology 789-3825 jdrempel@cc.umanitoba.ca 804D JBRC Topics: I. Types of Cell-Mediated Immunity II. Migration of Effector T Lymphocytes

More information

Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV)

Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) Amantadine and Rimantadine Use is limited to Influenza A infection. Very effective in preventing infection if

More information

Emerging Approaches for the Treatment of Hepatitis C Virus

Emerging Approaches for the Treatment of Hepatitis C Virus Emerging Approaches for the Treatment of Hepatitis C Virus Gap Analysis 1 Physicians may not be sufficiently familiar with the latest guidelines for chronic HCV treatment, including the initiation and

More information

Antivirals for the treatment of chronic HCV infection: Bench to Bedside and beyond

Antivirals for the treatment of chronic HCV infection: Bench to Bedside and beyond Antivirals for the treatment of chronic HCV infection: Bench to Bedside and beyond Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland Disclosures for

More information

The current recommended therapy for chronic

The current recommended therapy for chronic SPECIAL ARTICLE Mechanisms of Action of Interferon and Ribavirin in Chronic Hepatitis C: Summary of a Workshop Raymond T. Chung, 1 Michael Gale Jr, 2 Stephen J. Polyak, 2 Stanley M. Lemon, 3 T. Jake Liang,

More information

HCV Vaccine where do we stand? U. Spengler University of Bonn

HCV Vaccine where do we stand? U. Spengler University of Bonn HCV Vaccine where do we stand? U. Spengler University of Bonn THE IDEAL GOAL: The vaccine should induce sterilizing immunity A MORE REALISTIC GOAL: Prevention of chronic persistent infection Feinstone

More information

Towards a therapeutic HCV vaccine - a preclinical and clinical learning curve

Towards a therapeutic HCV vaccine - a preclinical and clinical learning curve Towards a therapeutic HCV vaccine - a preclinical and clinical learning curve Albufeira, June 1-6, 28 Alexander von Gabain For more information be invited to: www.intercell.com Chronic Hepatitis C: Standard

More information

windows of my lab Prof. Allan Wiik, emeritus director Department of Autoimmunology Statens Serum Institute, Copenhagen

windows of my lab Prof. Allan Wiik, emeritus director Department of Autoimmunology Statens Serum Institute, Copenhagen The normal immune system windows of my lab, Prof. Allan Wiik, emeritus director Department of Autoimmunology Statens Serum Institute, Copenhagen The immune defence Theinnateimmune system Cells: Eater cells

More information

Introduction to the Impact of Resistance in Hepatitis C

Introduction to the Impact of Resistance in Hepatitis C Introduction to the Impact of Resistance in Hepatitis C Sponsored by AbbVie 2/1/2017 Presented by Sammy Saab, MD, MPH, FACG, AGAF, FAASLD February 1 st, 2017 1 AbbVie disclosures This is an Abbvie sponsored

More information

COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16

COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 Tumor Immunology M. Nagarkatti Teaching Objectives: Introduction to Cancer Immunology Know the antigens expressed by cancer cells Understand

More information

Introduction. What Is the Immune System?

Introduction. What Is the Immune System? c h a p t e r The Immune System and The Hepatitis C Virus 7 Tina M. St. John, MD S E C T I O N 1 Meet the Immune System Introduction The immune system is the body s defense against infections. Think of

More information

Tumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)

Tumors arise from accumulated genetic mutations. Tumor Immunology (Cancer) Tumor Immunology (Cancer) Tumors arise from accumulated genetic mutations Robert Beatty MCB150 Mutations Usually have >6 mutations in both activation/growth factors and tumor suppressor genes. Types of

More information

Innate immunity (rapid response) Dendritic cell. Macrophage. Natural killer cell. Complement protein. Neutrophil

Innate immunity (rapid response) Dendritic cell. Macrophage. Natural killer cell. Complement protein. Neutrophil 1 The immune system The immune response The immune system comprises two arms functioning cooperatively to provide a comprehensive protective response: the innate and the adaptive immune system. The innate

More information

Corso di Laurea Specialistica in Biotecnologie Molecolari aa 2006/2007 Presentazione di Immunologia Molecolare INTERFERON GAMMA.

Corso di Laurea Specialistica in Biotecnologie Molecolari aa 2006/2007 Presentazione di Immunologia Molecolare INTERFERON GAMMA. Corso di Laurea Specialistica in Biotecnologie Molecolari aa 2006/2007 Presentazione di Immunologia Molecolare INTERFERON GAMMA Valentina Grosso The Inteferons 1957: Isaacs and Lindenmann discovered a

More information

Innate Immunity. Connection Between Innate and Adaptive Immunity. Know Differences and Provide Examples Chapter 3. Antimicrobial peptide psoriasin

Innate Immunity. Connection Between Innate and Adaptive Immunity. Know Differences and Provide Examples Chapter 3. Antimicrobial peptide psoriasin Know Differences and Provide Examples Chapter * Innate Immunity * kin and Epithelial Barriers * Antimicrobial peptide psoriasin -Activity against Gram (-) E. coli Connection Between Innate and Adaptive

More information

Allergic rhinitis (Hay fever) Asthma Anaphylaxis Urticaria Atopic dermatitis

Allergic rhinitis (Hay fever) Asthma Anaphylaxis Urticaria Atopic dermatitis Hypersensitivity Disorders Hypersensitivity Disorders Immune Response IgE Disease Example Ragweed hay fever IgG Cytotoxic Immune complex T Cell Hemolytic anemia Serum sickness Poison ivy IgE-mediated Diseases

More information

CYTOKINES. Based on: Cellular and Molecular Immunology, 4 th ed.,abbas A.K., Lichtman A.H. and Pober J.S. Sounders company; Philadelphia, 2010.

CYTOKINES. Based on: Cellular and Molecular Immunology, 4 th ed.,abbas A.K., Lichtman A.H. and Pober J.S. Sounders company; Philadelphia, 2010. CYTOKINES Based on: Cellular and Molecular Immunology, 4 th ed.,abbas A.K., Lichtman A.H. and Pober J.S. Sounders company; Philadelphia, 2010. 1 What are cytokines? Glycoproteins (15 25 kda): Interleukins

More information

Pharmacological management of viruses in obese patients

Pharmacological management of viruses in obese patients Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician

More information

Lecture 9: T-cell Mediated Immunity

Lecture 9: T-cell Mediated Immunity Lecture 9: T-cell Mediated Immunity Questions to Consider How do T cells know where to go? Questions to Consider How do T cells know where to go? How does antigen get targeted to a T cell expressing the

More information

Antiviral agents in HCV

Antiviral agents in HCV Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million

More information

Part III Innate and Adaptive Immune Cells: General Introduction

Part III Innate and Adaptive Immune Cells: General Introduction Innate and Adaptive Immune Cells: General Introduction Iván López-Expósito As an organ specialized in food digestion and nutrient absorption, the intestinal mucosa presents a huge surface area (almost

More information

Specifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C

Specifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C Specifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C Zobair M. Younossi, MD, MPH, FACP, FACG Medscape Gastroenterology. 2007; 2007 Medscape Posted 06/01/2007 Introduction

More information

Adaptive immune responses in acute and chronic hepatitis C virus infection David G. Bowen 1 and Christopher M. Walker 1,2

Adaptive immune responses in acute and chronic hepatitis C virus infection David G. Bowen 1 and Christopher M. Walker 1,2 Adaptive immune responses in acute and chronic hepatitis C virus infection David G. Bowen 1 and Christopher M. Walker 1,2 The hepatitis C virus (HCV) persists in the majority of infected individuals and

More information

Oncolytic Immunotherapy: A Local and Systemic Antitumor Approach

Oncolytic Immunotherapy: A Local and Systemic Antitumor Approach Oncolytic Immunotherapy: A Local and Systemic Antitumor Approach Oncolytic immunotherapy Oncolytic immunotherapy the use of a genetically modified virus to attack tumors and induce a systemic immune response

More information

Immunity. Acquired immunity differs from innate immunity in specificity & memory from 1 st exposure

Immunity. Acquired immunity differs from innate immunity in specificity & memory from 1 st exposure Immunity (1) Non specific (innate) immunity (2) Specific (acquired) immunity Characters: (1) Non specific: does not need special recognition of the foreign cell. (2) Innate: does not need previous exposure.

More information

HLA and antigen presentation. Department of Immunology Charles University, 2nd Medical School University Hospital Motol

HLA and antigen presentation. Department of Immunology Charles University, 2nd Medical School University Hospital Motol HLA and antigen presentation Department of Immunology Charles University, 2nd Medical School University Hospital Motol MHC in adaptive immunity Characteristics Specificity Innate For structures shared

More information

Chapter 13: Cytokines

Chapter 13: Cytokines Chapter 13: Cytokines Definition: secreted, low-molecular-weight proteins that regulate the nature, intensity and duration of the immune response by exerting a variety of effects on lymphocytes and/or

More information

HCV eradication with direct acting antivirals (DAAs)? Why is viral cure possible in HCV? Emilie Estrabaud

HCV eradication with direct acting antivirals (DAAs)? Why is viral cure possible in HCV? Emilie Estrabaud HCV eradication with direct acting antivirals (DAAs)? Why is viral cure possible in HCV? Emilie Estrabaud Service d Hépatologie et INSERM UMR1149, AP-HP Hôpital Beaujon, Paris, France. emilie.estrabaud@inserm.fr

More information

The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients

The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International

More information

Treatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D.

Treatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D. Session IV Treatment Options in HCV Relapsers and Nonresponders Raymond T. Chung, M.D. Director of Hepatology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Boston,

More information

Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition

Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research

More information

Advances in Hepatitis C Virus Therapeutics HBV HIV HCV. Advances in HCV Therapeutics. Greg Dore. Viral Hepatitis Clinical Research Program

Advances in Hepatitis C Virus Therapeutics HBV HIV HCV. Advances in HCV Therapeutics. Greg Dore. Viral Hepatitis Clinical Research Program Advances in Hepatitis C Virus Therapeutics Greg Dore Viral Hepatitis Clinical Research Program National Centre in HIV Epidemiology and Clinical Research Hepatitis C notifications: 199-23 Estimates of BBV

More information

The Use of Human Dendritic Cell

The Use of Human Dendritic Cell The Use of Human Dendritic Cell Subsets in Cancer Vaccines Jolien Sweere Student #: 3145298 Master Thesis Infection and Immunity Supervisor: Dr. Jeanette Leusen Immunotherapy University Medical Centre

More information

Immunology. Overview. Kris.ne Kra1s, M.D.

Immunology. Overview. Kris.ne Kra1s, M.D. Immunology Overview Kris.ne Kra1s, M.D. Immunology Overview Defini.ons Cells Lymphocytes An.gen-presen.ng cells Effector cells Responses The innate immune response Capturing and displaying an.gens Cell-mediated

More information